Japan Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of R/R DLBCL Announced June 23, 2026
Sarclisa SQ approved in the EU as the first anticancer treatment administered via an on-body injector June 17, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each With WELIREG, for Adjuvant Treatment of Certain Patients With Clear Cell RCC June 17, 2026
China NMPA Approves TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer June 17, 2026
Serplulimab Approved by NMPA for Perioperative Gastric Cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy June 17, 2026
European Commission Authorizes Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in 1L CLL June 2, 2026
DARZALEX® (daratumumab) injectable approved for administration by patients or caregivers for treatment of multiple myeloma June 2, 2026
Opdivo in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma June 2, 2026
Datroway approved in the US in 1L metastatic TNBC patients not PD-1/PD-L1 inhibitor candidates May 26, 2026
US FDA Approves INQOVI® in Combination with Venetoclax in AML Patients Ineligible for Intensive Induction Chemo May 21, 2026
Enhertu approved for use before surgery based on DESTINY-Breast11 Ph 3 trial and following surgery based on DESTINY-Breast05 Ph 3 trial in HER2-positive early breast cancer May 21, 2026
FDA Approves BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher May 12, 2026
FDA Approves VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer May 6, 2026
FDA Approves Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis May 6, 2026
Ojemda® approved in the EU in R/R pediatric low-grade glioma regardless of BRAF alteration April 28, 2026
ZEPZELCA + Tecentriq approved for use in Australia and Singapore as 1L maintenance treatment for adult patients with ES-SCLC April 21, 2026
Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma April 21, 2026
European Commission Approves KEYTRUDA + Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens April 7, 2026
Japan’s MHLW approves risovalisib (Risovalisib Mesilate Hydrate or Heitzexin) after chemo for ovarian clear cell carcinoma with advanced PIK3CA gene mutations March 31, 2026
FDA Approves Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer March 31, 2026
